Landmark Reform in U.S. Brings Mixed News for Healthcare Industry

Landmark Reform in U.S. Brings Mixed News for Healthcare Industry
 
Scranton, PA - March 30, 2010 - MedTRACK, a leading database of private and public biomedical companies, is predicting mixed news for the healthcare industry in the wake of the U.S. healthcare reform bill.
 
Key reform measures in the bill will have an impact on society, private insurers, branded pharmaceuticals, and generics. Measures such as the individual mandate, premium subsidies, Part D donut hole discounts/closure, and the biosimilars approval pathway will have both positive and negative effects on these stakeholders.
 
At the society level, people can expect to see increased access to healthcare which will, in turn, create increased customer volume to private insurers. Unfortunately, it's unlikely that expenditure growth can be contained facing this increase in market growth. Private insurers will also see a harsher competitive environment and lower profitability. Due to these changes in their business model, private insurers will seek out cost cutting and consolidation opportunities.
 
In the pharmaceutical industry, both branded and generics will experience volume growth. Generics, however, will face downward price pressures and later entry to market while branded pharmaceuticals will experience some hardships of their own. Reform measures will force branded pharma to endure greater cost-containment pressures along with drug discounts. The marketing activities of these companies will also suffer due to limitations the healthcare bill puts on marketing practices.
 
--Ends--
 
About MedTRACK
 
MedTRACK is the most comprehensive database of private and public biomedical companies. MedTRACK contains pipeline, financial, competitive product, mechanism of action, sales, partnering, and patent information on 18,634 biomedical companies worldwide.

The information can be sorted by parameters such as disease, competitive products, or clinical trial stage. Search functions reach into SEC filings, websites, business and product descriptions, journals, meeting abstracts, news, and announcements. MedTRACK makes it easy to find the data you need. Drill down on company fundamentals to establish an opinion, find partnering opportunities, or respond with educated agility to market news.
 
Visit MedTRACK to learn more: www.medtrack.com
 
Notes to Editors:
 
Sarah Terry, President, Life Science Analytics, is available for comment. To arrange an interview, please contact Alan Sott in the MedTRACK press office at + 1 570 687 9315 or send an email to [email protected]
 
For U.S. and Europe, contact Alan Sott at +1 570 687 9315 or send an email to [email protected]
 
For Asia-Pacific, please call Tanisha Kaul on +61 (0) 3 9601 6723 or email [email protected]
 
For India and MENA, please call Aartee Sundheep on +91 406 672 9586 or email [email protected]

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.